Paraoxonase 1 (PON1) reduces macrophage inflammatory responses

Atherosclerosis

Volumn 228, Issue 2, 2013, Pages 353-361

  Aharoni, Saar ^a   Aviram, Michael ^a   Fuhrman, Bianca ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Atherosclerosis; Inflammation; M1 activation; Macrophages; Paraoxonase 1 (PON1)

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; EX VIVO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ARYLDIALKYLPHOSPHATASE; CELL LINE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NECROSIS; OXIDATIVE STRESS; PHAGOCYTOSIS; PHENOTYPE; REACTIVE OXYGEN SPECIES; SCAVENGER RECEPTORS, CLASS B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878113868     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.03.005     Document Type: Article

References (32)

1. Ross R. Atherosclerosis - an inflammatory disease. NEngl J Med 1999, 340:115-126.
2. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
3. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci 2008, 13:453-461.
4. Bouhlel M.A., Derudas B., Rigamonti E., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007, 6:137-143.
5. Mantovani A., Garlanda C., Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009, 29:1419-1423.
6. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Franceschini G., James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. JBiol Chem 2002, 277:4301-4308.
7. Tward A., Xia Y.R., Wang X.P., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002, 106:484-490.
8. Aviram M., Kaplan M., Rosenblat M., Fuhrman B. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharmacol 2005, 170:263-300.
9. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. JClin Invest 1998, 101:1581-1590.
10. Rozenberg O., Shih D.M., Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005, 181:9-18.
11. Berrougui H., Loued S., Khalil A. Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages. Free Radic Biol Med 2012, 52:1372-1381.
12. Tavori H., Vaya J., Aviram M. Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity. Adv Exp Med Biol 2010, 660:99-111.
13. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. JClin Invest 1995, 96:2882-2891.
14. Ahmed Z., Babaei S., Maguire G.F., et al. Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. Cardiovasc Res 2003, 57:225-231.
15. Rosenblat M., Volkova N., Ward J., Aviram M. Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation. Atherosclerosis 2011, 219:49-56.
16. Ng D.S., Chu T., Esposito B., Hui P., Connelly P.W., Gross P.L. Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovasc Pathol 2008, 17:226-232.
17. Efrat M., Aviram M. Macrophage paraoxonase 1 (PON1) binding sites. Biochem Biophys Res Commun 2008, 376:105-110.
18. Khersonsky O., Tawfik D.S. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. JBiol Chem 2006, 281:7649-7656.
19. Deakin S.P., Bioletto S., Bochaton-Piallat M.L., James R.W. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radic Biol Med 2011, 50:102-109.
20. Chen Y.J., Hsieh M.Y., Chang M.Y., et al. Eps8 protein facilitates phagocytosis by increasing TLR4-MyD88 protein interaction in lipopolysaccharide-stimulated macrophages. JBiol Chem 2012, 287:18806-18819.
21. Nieland T.J., Shaw J.T., Jaipuri F.A., et al. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. Biochemistry 2008, 47:460-472.
22. Fuhrman B., Gantman A., Aviram M. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 2010, 211:61-68.
23. Cai L., Wang Z., Ji A., Meyer J.M., van der Westhuyzen D.R. Macrophage SR-BI regulates pro-inflammatory signaling in mice and isolated macrophages. JLipid Res 2012, 53:1472-1481.
24. Zhu P., Liu X., Treml L.S., Cancro M.P., Freedman B.D. Mechanism and regulatory function of CpG signaling via scavenger receptor B1 in primary B cells. JBiol Chem 2009, 284:22878-22887.
25. Saddar S., Mineo C., Shaul P.W. Signaling by the high-affinity HDL receptor scavenger receptor B type I. Arterioscler Thromb Vasc Biol 2010, 30:144-150.
26. Guo L., Song Z., Li M., et al. Scavenger receptor BI protects against septic death through its role in modulating inflammatory response. JBiol Chem 2009, 284(30):19826-19834.
27. Seimon T., Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. JLipid Res 2009, 50(Suppl.):S382-S387.
28. Yan Z.Q., Hansson G.K. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007, 219:187-203.
29. Baitsch D., Bock H.H., Engel T., et al. Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol 2011, 31:1160-1168.
30. Chinetti-Gbaguidi G., Baron M., Bouhlel M.A., et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ Res 2011, 108:985-995.
31. Mosser D.M. The many faces of macrophage activation. JLeukoc Biol 2003, 73:209-212.
32. Gordon S. Macrophage heterogeneity and tissue lipids. JClin Invest 2007, 117:89-93.